Richard H Myers

List of Publications by Year in Descending Order

Source: https://exaly.com/author-pdf/6398424/richard-h-myers-publications-by-year.pdf
Version: 2024-04-23

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

219 papers	30,080 citations	75 h-index	172 g-index
225 ext. papers	33,230 ext. citations	9.1 avg, IF	6.92 L-index

#	Paper	IF	Citations
219	Genomewide Association Studies of LRRK2 Modifiers of Parkinson's Disease. *Annals of Neurology*, **2021**, 90, 76-88	9.4	9
218	Dysfunction of X-linked inhibitor of apoptosis protein (XIAP) triggers neuropathological processes via altered p53 activity in Huntington's disease. *Progress in Neurobiology*, **2021**, 204, 102110	10.9	0
217	Genetic Risk Underlying Psychiatric and Cognitive Symptoms in Huntington's Disease. *Biological Psychiatry*, **2020**, 87, 857-865	7.9	13
216	A glycomics and proteomics study of aging and Parkinson's disease in human brain. *Scientific Reports*, **2020**, 10, 12804	4.9	15
215	CAG Repeat Not Polyglutamine Length Determines Timing of Huntington's Disease Onset. *Cell*, **2019**, 178, 887-900.e14	56.2	155
214	The caudate nucleus undergoes dramatic and unique transcriptional changes in human prodromal Huntington's disease brain. *BMC Medical Genomics*, **2019**, 12, 137	3.7	17
213	MicroRNAs in CSF as prodromal biomarkers for Huntington disease in the PREDICT-HD study. *Neurology*, **2018**, 90, e264-e272	6.5	39
212	Functional variants in the gene confer shared effects on risk for Crohn's disease and Parkinson's disease. *Science Translational Medicine*, **2018**, 10,	17.5	165
211	Multiethnic meta-analysis identifies ancestry-specific and cross-ancestry loci for pulmonary function. *Nature Communications*, **2018**, 9, 2976	17.4	45
210	Huntington Disease **2017**, 503-516		1
209	The pathogenic exon 1 HTT protein is produced by incomplete splicing in Huntington's disease patients. *Scientific Reports*, **2017**, 7, 1307	4.9	89
208	Evidence for a Pan-Neurodegenerative Disease Response in Huntington's and Parkinson's Disease Expression Profiles. *Frontiers in Molecular Neuroscience*, **2017**, 10, 430	6.1	18
207	Haplotype-based stratification of Huntington's disease. *European Journal of Human Genetics*, **2017**, 25, 1202-1209	5.3	14
206	Evaluation of logistic regression models and effect of covariates for case-control study in RNA-Seq analysis. *BMC Bioinformatics*, **2017**, 18, 91	3.6	11
205	A modifier of Huntington's disease onset at the MLH1 locus. *Human Molecular Genetics*, **2017**, 26, 3859-3867	5.6	59
204	Novel microRNA discovery using small RNA sequencing in post-mortem human brain. *BMC Genomics*, **2016**, 17, 776	4.5	20
203	Genome-wide meta-analysis uncovers novel loci influencing circulating leptin levels. *Nature Communications*, **2016**, 7, 10494	17.4	107

202	Integrative analyses of proteomics and RNA transcriptomics implicate mitochondrial processes, protein folding pathways and GWAS loci in Parkinson disease. *BMC Medical Genomics*, **2016**, 9, 5	3.7	57
201	The 4p16.3 Parkinson Disease Risk Locus Is Associated with GAK Expression and Genes Involved with the Synaptic Vesicle Membrane. *PLoS ONE*, **2016**, 11, e0160925	3.7	14
200	microRNA Profiles in Parkinson's Disease Prefrontal Cortex. *Frontiers in Aging Neuroscience*, **2016**, 8, 36	5.3	96
199	B4 Detection of the aberrantly spliced exon 1 intron 1 htt mRNA in HD patient post mortem brain tissue and fibroblast lines. *Journal of Neurology, Neurosurgery and Psychiatry*, **2016**, 87, A10.2-A10	5.5	
198	Parkinson-associated risk variant in distal enhancer of synuclein modulates target gene expression. *Nature*, **2016**, 533, 95-9	50.4	360
197	DNM3 and genetic modifiers of age of onset in LRRK2 Gly2019Ser parkinsonism: a genome-wide linkage and association study. *Lancet Neurology, The*, **2016**, 15, 1248-1256	24.1	50
196	Novel Genetic Variants Associated With Increased Vertebral Volumetric BMD, Reduced Vertebral Fracture Risk, and Increased Expression of SLC1A3 and EPHB2. *Journal of Bone and Mineral Research*, **2016**, 31, 2085-2097	6.3	33
195	Directional dominance on stature and cognition in diverse human populations. *Nature*, **2015**, 523, 459-462	50.4	119
194	miR-10b-5p expression in Huntington's disease brain relates to age of onset and the extent of striatal involvement. *BMC Medical Genomics*, **2015**, 8, 10	3.7	76
193	Sequence-Level Analysis of the Major European Huntington Disease Haplotype. *American Journal of Human Genetics*, **2015**, 97, 435-44	11	14
192	Epigenetic dysregulation of hairy and enhancer of split 4 (HES4) is associated with striatal degeneration in postmortem Huntington brains. *Human Molecular Genetics*, **2015**, 24, 1441-56	5.6	52
191	The Genetic Modifiers of Motor OnsetAge (GeM MOA) Website: Genome-wide Association Analysis for Genetic Modifiers of Huntington's Disease. *Journal of Huntington's Disease*, **2015**, 4, 279-84	1.9	20
190	Study of plasma-derived miRNAs mimic differences in Huntington's disease brain. *Movement Disorders*, **2015**, 30, 1961-4	7	24
189	RNA Sequence Analysis of Human Huntington Disease Brain Reveals an Extensive Increase in Inflammatory and Developmental Gene Expression. *PLoS ONE*, **2015**, 10, e0143563	3.7	99
188	Evidence of Extensive Alternative Splicing in Post Mortem Human Brain HTT Transcription by mRNA Sequencing. *PLoS ONE*, **2015**, 10, e0141298	3.7	13
187	The Role of H3K4me3 in Transcriptional Regulation Is Altered in Huntington's Disease. *PLoS ONE*, **2015**, 10, e0144398	3.7	33
186	Large-scale meta-analysis of genome-wide association data identifies six new risk loci for Parkinson's disease. *Nature Genetics*, **2014**, 46, 989-93	36.3	1261
185	MicroRNAs located in the Hox gene clusters are implicated in huntington's disease pathogenesis. *PLoS Genetics*, **2014**, 10, e1004188	6	73

184	Correction for multiple testing in a gene region. *European Journal of Human Genetics*, **2014**, 22, 414-8	5.3	29
183	Conserved higher-order chromatin regulates NMDA receptor gene expression and cognition. *Neuron*, **2014**, 84, 997-1008	13.9	60
182	Candidate glutamatergic and dopaminergic pathway gene variants do not influence Huntington's disease motor onset. *Neurogenetics*, **2013**, 14, 173-9	3	9
181	Serum iron levels and the risk of Parkinson disease: a Mendelian randomization study. *PLoS Medicine*, **2013**, 10, e1001462	11.6	80
180	Assessment of cortical and striatal involvement in 523 Huntington disease brains. *Neurology*, **2012**, 79, 1708-15	6.5	48
179	Population stratification may bias analysis of PGC-1 as a modifier of age at Huntington disease motor onset. *Human Genetics*, **2012**, 131, 1833-40	6.3	25
178	TAA repeat variation in the GRIK2 gene does not influence age at onset in Huntington's disease. *Biochemical and Biophysical Research Communications*, **2012**, 424, 404-8	3.4	17
177	Human-specific histone methylation signatures at transcription start sites in prefrontal neurons. *PLoS Biology*, **2012**, 10, e1001427	9.7	97
176	Genetic signatures of exceptional longevity in humans. *PLoS ONE*, **2012**, 7, e29848	3.7	270
175	Evaluation of Parkinson disease risk variants as expression-QTLs. *PLoS ONE*, **2012**, 7, e46199	3.7	27
174	Postmortem Interval Influences Synuclein Expression in Parkinson Disease Brain. *Parkinson's Disease*, **2012**, 2012, 614212	2.6	11
173	Meta-analysis of Parkinson's disease: identification of a novel locus, RIT2. *Annals of Neurology*, **2012**, 71, 370-84	9.4	214
172	Common SNP-based haplotype analysis of the 4p16.3 Huntington disease gene region. *American Journal of Human Genetics*, **2012**, 90, 434-44	11	48
171	Gene expression profiles in Parkinson disease prefrontal cortex implicate FOXO1 and genes under its transcriptional regulation. *PLoS Genetics*, **2012**, 8, e1002794	6	54
170	Comprehensive research synopsis and systematic meta-analyses in Parkinson's disease genetics: The PDGene database. *PLoS Genetics*, **2012**, 8, e1002548	6	420
169	Genome-wide association studies identify CHRNA5/3 and HTR4 in the development of airflow obstruction. *American Journal of Respiratory and Critical Care Medicine*, **2012**, 186, 622-32	10.2	131
168	Generation of isogenic pluripotent stem cells differing exclusively at two early onset Parkinson point mutations. *Cell*, **2011**, 146, 318-31	56.2	603
167	Genomewide linkage study of modifiers of LRRK2-related Parkinson's disease. *Movement Disorders*, **2011**, 26, 2039-44	7	7

166	Cyclin-G-associated kinase modifies α-synuclein expression levels and toxicity in Parkinson's disease: results from the GenePD Study. *Human Molecular Genetics*, **2011**, 20, 1478-87	5.6	47
165	Copy number variation in familial Parkinson disease. *PLoS ONE*, **2011**, 6, e20988	3.7	53
164	Association analyses of 249,796 individuals reveal 18 new loci associated with body mass index. *Nature Genetics*, **2010**, 42, 937-48	36.3	2267
163	Estrogen-related and other disease diagnoses preceding Parkinson's disease. *Clinical Epidemiology*, **2010**, 2, 153-70	5.9	6
162	Decreased glutamic acid decarboxylase mRNA expression in prefrontal cortex in Parkinson's disease. *Experimental Neurology*, **2010**, 226, 207-17	5.7	34
161	Risk of Parkinson's disease after tamoxifen treatment. *BMC Neurology*, **2010**, 10, 23	3.1	25
160	A genome-wide association study of pulmonary function measures in the Framingham Heart Study. *PLoS Genetics*, **2009**, 5, e1000429	6	242
159	The association of cell cycle checkpoint 2 variants and kidney function: findings of the Family Blood Pressure Program and the Atherosclerosis Risk In Communities study. *American Journal of Hypertension*, **2009**, 22, 552-8	2.3	1
158	Leptin is associated with blood pressure and hypertension in women from the National Heart, Lung, and Blood Institute Family Heart Study. *Hypertension*, **2009**, 53, 473-9	8.5	55
157	Somatic expansion of the Huntington's disease CAG repeat in the brain is associated with an earlier age of disease onset. *Human Molecular Genetics*, **2009**, 18, 3039-47	5.6	198
156	Genetic effect on blood pressure is modulated by age: the Hypertension Genetic Epidemiology Network Study. *Hypertension*, **2009**, 53, 35-41	8.5	53
155	Estimating the probability of de novo HD cases from transmissions of expanded penetrant CAG alleles in the Huntington disease gene from male carriers of high normal alleles (27-35 CAG). *American Journal of Medical Genetics, Part A*, **2009**, 149A, 1375-81	2.5	39
154	Genomewide association study for susceptibility genes contributing to familial Parkinson disease. *Human Genetics*, **2009**, 124, 593-605	6.3	363
153	Genomewide association study for onset age in Parkinson disease. *BMC Medical Genetics*, **2009**, 10, 98	2.1	78
152	A QTL on 12q influencing an inflammation marker and obesity in white women: the NHLBI Family Heart Study. *Obesity*, **2009**, 17, 525-31	8	10
151	Multiple genes influence BMI on chromosome 7q31-34: the NHLBI Family Heart Study. *Obesity*, **2009**, 17, 2182-9	8	15
150	Evidence for three novel QTLs for adiposity on chromosome 2 with epistatic interactions: the NHLBI Family Heart Study. *Obesity*, **2009**, 17, 2190-5	8	4
149	LIPC variants in the promoter and intron 1 modify HDL-C levels in a sex-specific fashion. *Atherosclerosis*, **2009**, 204, 171-7	3.1	11

148	NYD-SP18 is associated with obesity in the NHLBI Family Heart Study. *International Journal of Obesity*, **2008**, 32, 930-5	5.5	8
147	The Gly2019Ser mutation in LRRK2 is not fully penetrant in familial Parkinson's disease: the GenePD study. *BMC Medicine*, **2008**, 6, 32	11.4	72
146	Circulating soluble ICAM-1 levels shows linkage to ICAM gene cluster region on chromosome 19: the NHLBI Family Heart Study follow-up examination. *Atherosclerosis*, **2008**, 199, 172-8	3.1	14
145	Replication of association between ELAVL4 and Parkinson disease: the GenePD study. *Human Genetics*, **2008**, 124, 95-9	6.3	28
144	Polymorphisms near EXOC4 and LRGUK on chromosome 7q32 are associated with Type 2 Diabetes and fasting glucose; the NHLBI Family Heart Study. *BMC Medical Genetics*, **2008**, 9, 46	2.1	15
143	Huntington CAG repeat size does not modify onset age in familial Parkinson's disease: the GenePD study. *Movement Disorders*, **2008**, 23, 1596-601	7	7
142	Genome-wide admixture mapping for coronary artery calcification in African Americans: the NHLBI Family Heart Study. *Genetic Epidemiology*, **2008**, 32, 264-72	2.6	10
141	Comprehensive linkage and linkage heterogeneity analysis of 4344 sibling pairs affected with hypertension from the Family Blood Pressure Program. *Genetic Epidemiology*, **2007**, 31, 195-210	2.6	6
140	Circulating MCP-1 levels shows linkage to chemokine receptor gene cluster on chromosome 3: the NHLBI family heart study follow-up examination. *Genes and Immunity*, **2007**, 8, 684-90	4.4	16
139	The relationship between CAG repeat length and age of onset differs for Huntington's disease patients with juvenile onset or adult onset. *Annals of Human Genetics*, **2007**, 71, 295-301	2.2	89
138	Sepiapterin reductase expression is increased in Parkinson's disease brain tissue. *Brain Research*, **2007**, 1139, 42-7	3.7	22
137	Factors associated with HD CAG repeat instability in Huntington disease. *Journal of Medical Genetics*, **2007**, 44, 695-701	5.8	86
136	Genotype-by-sex interaction on fasting insulin concentration: the HyperGEN study. *Diabetes*, **2007**, 56, 137-42	0.9	18
135	HaploBuild: an algorithm to construct non-contiguous associated haplotypes in family based genetic studies. *Bioinformatics*, **2007**, 23, 2190-2	7.2	12
134	The etiopathogenesis of Parkinson disease and suggestions for future research. Part I. *Journal of Neuropathology and Experimental Neurology*, **2007**, 66, 251-7	3.1	88
133	The etiopathogenesis of Parkinson disease and suggestions for future research. Part II. *Journal of Neuropathology and Experimental Neurology*, **2007**, 66, 329-36	3.1	38
132	LRRK2 is not a significant cause of Parkinson's disease in French-Canadians. *Canadian Journal of Neurological Sciences*, **2007**, 34, 333-5	1	5
131	Evidence of QTL on 15q21 for high-density lipoprotein cholesterol: the National Heart, Lung, and Blood Institute Family Heart Study (NHLBI FHS). *Atherosclerosis*, **2007**, 190, 232-7	3.1	8

130	Genotype-by-sex interaction in the aetiology of type 2 diabetes mellitus: support for sex-specific quantitative trait loci in Hypertension Genetic Epidemiology Network participants. *Diabetologia*, **2006**, 49, 2329-36	10.3	19
129	Brain-derived neurotrophic factor does not influence age at neurologic onset of Huntington's disease. *Neurobiology of Disease*, **2006**, 24, 280-5	7.5	29
128	Genetic analysis of the GRIK2 modifier effect in Huntington's disease. *BMC Neuroscience*, **2006**, 7, 62	3.2	15
127	Influence of heterozygosity for parkin mutation on onset age in familial Parkinson disease: the GenePD study. *Archives of Neurology*, **2006**, 63, 826-32		131
126	Quantitative trait loci on chromosome 8q24 for pancreatic beta-cell function and 7q11 for insulin sensitivity in obese nondiabetic white and black families: evidence from genome-wide linkage scans in the NHLBI Hypertension Genetic Epidemiology Network (HyperGEN) study. *Diabetes*, **2006**, 55, 551-8	0.9	15
125	Genetic background modifies nuclear mutant huntingtin accumulation and HD CAG repeat instability in Huntington's disease knock-in mice. *Human Molecular Genetics*, **2006**, 15, 2015-24	5.6	68
124	Considerations for genomewide association studies in Parkinson disease. *American Journal of Human Genetics*, **2006**, 78, 1081-2	11	30
123	Longitudinal and age trends of metabolic syndrome and its risk factors: the Family Heart Study. *Nutrition and Metabolism*, **2006**, 3, 41	4.6	42
122	Evidence for a gene influencing heart rate on chromosome 5p13-14 in a meta-analysis of genome-wide scans from the NHLBI Family Blood Pressure Program. *BMC Medical Genetics*, **2006**, 7, 17	2.1	10
121	Genome-wide significance for a modifier of age at neurological onset in Huntington's disease at 6q23-24: the HD MAPS study. *BMC Medical Genetics*, **2006**, 7, 71	2.1	62
120	Adrenergic receptor polymorphisms associated with resting heart rate: the HyperGEN Study. *Annals of Human Genetics*, **2006**, 70, 566-73	2.2	23
119	An evaluation of the metabolic syndrome in the HyperGEN study. *Nutrition and Metabolism*, **2005**, 2, 2	4.6	34
118	Quantitative trait loci for metabolic syndrome in the Hypertension Genetic Epidemiology Network study. *Obesity*, **2005**, 13, 1885-90		16
117	A haplotype similarity based transmission/disequilibrium test under founder heterogeneity. *Annals of Human Genetics*, **2005**, 69, 455-67	2.2	11
116	HD CAG repeat implicates a dominant property of huntingtin in mitochondrial energy metabolism. *Human Molecular Genetics*, **2005**, 14, 2871-80	5.6	246
115	Monozygotic twins discordant for Huntington disease after 7 years. *Archives of Neurology*, **2005**, 62, 995-7		38
114	Apolipoprotein E polymorphism modifies the alcohol-HDL association observed in the National Heart, Lung, and Blood Institute Family Heart Study. *American Journal of Clinical Nutrition*, **2004**, 80, 1639-44	7	26
113	Genome-wide scan identifies novel QTLs for cholesterol and LDL levels in F2[Dahl RxS]-intercross rats. *Circulation Research*, **2004**, 94, 446-52	15.7	12

112	Linkage analysis of diabetes status among hypertensive families: the Hypertension Genetic Epidemiology Network study. *Diabetes*, **2004**, 53, 3307-12	0.9	16
111	Evidence for a modifier of onset age in Huntington disease linked to the HD gene in 4p16. *Neurogenetics*, **2004**, 5, 109-14	3	63
110	Huntington's disease genetics. *NeuroRx*, **2004**, 1, 255-62		231
109	Genome-wide linkage analyses for age at diagnosis of hypertension and early-onset hypertension in the HyperGEN study. *American Journal of Hypertension*, **2004**, 17, 839-44	2.3	25
108	Common variants in the 5' region of the leptin gene are associated with body mass index in men from the National Heart, Lung, and Blood Institute Family Heart Study. *American Journal of Human Genetics*, **2004**, 75, 220-30	11	73
107	Huntington disease genetics. *Neurotherapeutics*, **2004**, 1, 255-262	6.4	
106	Genomewide linkage analysis to presbycusis in the Framingham Heart Study. *JAMA Otolaryngology*, **2003**, 129, 285-9		69
105	A genome-wide scan of pulmonary function measures in the National Heart, Lung, and Blood Institute Family Heart Study. *American Journal of Respiratory and Critical Care Medicine*, **2003**, 167, 1528-33	19.2	38
104	A genome-wide scan for loci affecting normal adult height in the Framingham Heart Study. *Human Heredity*, **2003**, 55, 191-201	1.1	23
103	A genome scan for loci linked to quantitative insulin traits in persons without diabetes: the Framingham Offspring Study. *Diabetologia*, **2003**, 46, 579-87	10.3	41
102	State of the art review: molecular diagnosis of inherited movement disorders. Movement Disorders Society task force on molecular diagnosis. *Movement Disorders*, **2003**, 18, 3-18	7	30
101	The analysis of survival data with a non-susceptible fraction and dual censoring mechanisms. *Statistics in Medicine*, **2003**, 22, 3249-62	2.3	4
100	Combined analysis of genomewide scans for adult height: results from the NHLBI Family Blood Pressure Program. *European Journal of Human Genetics*, **2003**, 11, 271-4	5.3	36
99	A genome scan for modifiers of age at onset in Huntington disease: The HD MAPS study. *American Journal of Human Genetics*, **2003**, 73, 682-7	11	131
98	Linkage analysis of a composite factor for the multiple metabolic syndrome: the National Heart, Lung, and Blood Institute Family Heart Study. *Diabetes*, **2003**, 52, 2840-7	0.9	78
97	Linkage and association with pulmonary function measures on chromosome 6q27 in the Framingham Heart Study. *Human Molecular Genetics*, **2003**, 12, 2745-51	5.6	29
96	Mapping of quantitative ultrasound of the calcaneus bone to chromosome 1 by genome-wide linkage analysis. *Osteoporosis International*, **2002**, 13, 796-802	5.3	52
95	A genome-wide screen reveals evidence for a locus on chromosome 11 influencing variation in LDL cholesterol in the NHLBI Family Heart Study. *Human Genetics*, **2002**, 111, 263-9	6.3	25

94	Evidence for a gene influencing heart rate on chromosome 4 among hypertensives. *Human Genetics* , **2002**, 111, 207-13	6.3	22
93	Is DFNA5 a susceptibility gene for age-related hearing impairment?. *European Journal of Human Genetics*, **2002**, 10, 883-6	5.3	24
92	Genetic variability of adult body mass index: a longitudinal assessment in framingham families. *Obesity*, **2002**, 10, 675-81		46
91	Genome screen for quantitative trait loci contributing to normal variation in bone mineral density: the Framingham Study. *Journal of Bone and Mineral Research*, **2002**, 17, 1718-27	6.3	107
90	A genome-wide scan for loci linked to plasma levels of glucose and HbA(1c) in a community-based sample of Caucasian pedigrees: The Framingham Offspring Study. *Diabetes*, **2002**, 51, 833-40	0.9	160
89	Influence of apolipoprotein E, smoking, and alcohol intake on carotid atherosclerosis: National Heart, Lung, and Blood Institute Family Heart Study. *Stroke*, **2002**, 33, 1357-61	6.7	80
88	Genetic loci influencing lung function: a genome-wide scan in the Framingham Study. *American Journal of Respiratory and Critical Care Medicine*, **2002**, 165, 795-9	10.2	64
87	Quantitative-trait loci influencing body-mass index reside on chromosomes 7 and 13: the National Heart, Lung, and Blood Institute Family Heart Study. *American Journal of Human Genetics*, **2002**, 70, 72-82	11	128
86	PARK3 influences age at onset in Parkinson disease: a genome scan in the GenePD study. *American Journal of Human Genetics*, **2002**, 70, 1089-95	11	81
85	Absence of linkage or association for osteoarthritis with the vitamin D receptor/type II collagen locus: the Framingham Osteoarthritis Study. *Journal of Rheumatology*, **2002**, 29, 161-5	4.1	19
84	Juvenile onset Huntington's disease--clinical and research perspectives. *Mental Retardation and Developmental Disabilities Research Reviews*, **2001**, 7, 153-7		121
83	Quantitative neuropathological changes in presymptomatic Huntington's disease. *Annals of Neurology*, **2001**, 49, 29-34	9.4	141
82	Interaction of alpha(1)-Na,K-ATPase and Na,K,2Cl-cotransporter genes in human essential hypertension. *Hypertension*, **2001**, 38, 204-9	8.5	48
81	Genome-wide linkage analysis of lipids in the Hypertension Genetic Epidemiology Network (HyperGEN) Blood Pressure Study. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2001**, 21, 1969-76	9.4	63
80	Genome scan for quantitative trait loci linked to high-density lipoprotein cholesterol: The NHLBI Family Heart Study. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2001**, 21, 1823-8	9.4	58
79	Genetic and environmental contributions to platelet aggregation: the Framingham heart study. *Circulation*, **2001**, 103, 3051-6	16.7	184
78	Heritability of longitudinal change in lung function. The Framingham study. *American Journal of Respiratory and Critical Care Medicine*, **2001**, 164, 1655-9	10.2	52
77	Association of plasma bilirubin with coronary heart disease and segregation of bilirubin as a major gene trait: the NHLBI family heart study. *Atherosclerosis*, **2001**, 154, 747-54	3.1	68

76	Evidence for major genes influencing pulmonary function in the NHLBI family heart study. *Genetic Epidemiology*, **2000**, 19, 81-94	2.6	89
75	Genetic background of Lewis negative blood group phenotype and its association with atherosclerotic disease in the NHLBI family heart study. *Journal of Internal Medicine*, **2000**, 247, 689-98	10.8	19
74	Absence of linkage for bone mineral density to chromosome 12q12-14 in the region of the vitamin D receptor gene. *Calcified Tissue International*, **2000**, 67, 434-9	3.9	11
73	Smoking influences the association between apolipoprotein E and lipids: the National Heart, Lung, and Blood Institute Family Heart Study. *Lipids*, **2000**, 35, 827-31	1.6	12
72	Evidence for a gene influencing blood pressure on chromosome 17. Genome scan linkage results for longitudinal blood pressure phenotypes in subjects from the framingham heart study. *Hypertension*, **2000**, 36, 477-83	8.5	483
71	Replication of linkage of familial combined hyperlipidemia to chromosome 1q with additional heterogeneous effect of apolipoprotein A-I/C-III/A-IV locus. The NHLBI Family Heart Study. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2000**, 20, 2275-80	9.4	77
70	Evidence for a gene influencing the TG/HDL-C ratio on chromosome 7q32.3-qter: a genome-wide scan in the Framingham study. *Human Molecular Genetics*, **2000**, 9, 1315-20	5.6	88
69	Insulin and hypertension in the NHLBI Family Heart Study: a sibpair approach to a controversial issue. *American Journal of Hypertension*, **2000**, 13, 240-50	2.3	8
68	No evidence of linkage between the very-low-density lipoprotein receptor gene and fasting serum insulin or homeostasis model assessment insulin resistance index: the National Heart, Lung, and Blood Institute Family Heart Study. *Metabolism: Clinical and Experimental*, **2000**, 49, 293-7	12.7	1
67	Increased platelet aggregability associated with platelet GPIIIa PlA2 polymorphism: the Framingham Offspring Study. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **1999**, 19, 1142-7	9.4	217
66	Genetic associations in age-related hearing thresholds. *JAMA Otolaryngology*, **1999**, 125, 654-9		231
65	Evidence for a major gene accounting for mild elevation in LDL cholesterol: the NHLBI Family Heart Study. *Annals of Human Genetics*, **1999**, 63, 401-12	2.2	12
64	Lewis blood group phenotype as an independent risk factor for coronary heart disease (the NHLBI Family Heart Study). *American Journal of Cardiology*, **1999**, 83, 345-8	3	23
63	Absence of effect of seven functional mutations in the CYP2D6 gene in Parkinson's disease. *Movement Disorders*, **1999**, 14, 590-5	7	14
62	Effects of similarities in lifestyle habits on familial aggregation of high density lipoprotein and low density lipoprotein cholesterol: the NHLBI Family Heart Study. *American Journal of Epidemiology*, **1999**, 150, 910-8	3.8	26
61	Parental age at child's birth and son's risk of prostate cancer. The Framingham Study. *American Journal of Epidemiology*, **1999**, 150, 1208-12	3.8	66
60	Evidence for a Mendelian gene in a segregation analysis of generalized radiographic osteoarthritis: the Framingham Study. *Arthritis and Rheumatism*, **1998**, 41, 1064-71		166
59	Beta-glucocerebrosidase gene locus as a link for Gaucher's disease and familial hypo-alpha-lipoproteinaemia. *Lancet, The*, **1998**, 351, 1919-23	40	41

58	Laboratory Guidelines for Huntington Disease Genetic Testing. *American Journal of Human Genetics* , **1998**, 62, 1243-1247	11	166
57	Evidence for association and genetic linkage of the angiotensin-converting enzyme locus with hypertension and blood pressure in men but not women in the Framingham Heart Study. *Circulation*, **1998**, 97, 1766-72	16.7	442
56	Angiotensinogen and angiotensin converting enzyme genotypes and carotid atherosclerosis: the atherosclerosis risk in communities and the NHLBI family heart studies. *Atherosclerosis*, **1998**, 138, 111-6	3.1	30
55	Segregation analysis of pulmonary function among families in the Framingham Study. *American Journal of Respiratory and Critical Care Medicine*, **1998**, 157, 1445-51	10.2	84
54	Effects of Age and Ethnicity on the Link Between APOE ?4 and Alzheimer Disease—Reply. *JAMA - Journal of the American Medical Association*, **1998**, 279, 581	27.4	2
53	Reduced penetrance of the Huntington's disease mutation. *Human Molecular Genetics*, **1997**, 6, 775-9	5.6	122
52	The BsmI vitamin D receptor restriction fragment length polymorphism (bb) influences the effect of calcium intake on bone mineral density. *Journal of Bone and Mineral Research*, **1997**, 12, 1049-57	6.3	100
51	CAG repeat number governs the development rate of pathology in Huntington's disease. *Annals of Neurology*, **1997**, 41, 689-92	9.4	512
50	Long-term impact of Huntington disease linkage testing **1997**, 70, 365-370		27
49	Detecting linkage for a complex disease using simulated extended pedigrees. *Genetic Epidemiology*, **1997**, 14, 981-6	2.6	1
48	Heritability of left ventricular mass: the Framingham Heart Study. *Hypertension*, **1997**, 30, 1025-8	8.5	128
47	Familial history of stroke and stroke risk. The Family Heart Study. *Stroke*, **1997**, 28, 1908-12	6.7	111
46	Incomplete dominance of type III hyperlipoproteinemia is associated with the rare apolipoprotein E2 (Arg136-->Ser) variant in multigenerational pedigree studies. *Atherosclerosis*, **1996**, 122, 33-46	3.1	31
45	Evidence of cortical metabolic dysfunction in early Huntington's disease by single-photon-emission computed tomography. *Movement Disorders*, **1996**, 11, 671-7	7	53
44	Absence of association or genetic linkage between the angiotensin-converting-enzyme gene and left ventricular mass. *New England Journal of Medicine*, **1996**, 334, 1023-8	59.2	201
43	Normal and Expanded Huntington's Disease Gene Alleles Produce Distinguishable Proteins Due to Translation Across the CAG Repeat. *Molecular Medicine*, **1995**, 1, 374-383	6.2	90
42	Single sperm analysis of the trinucleotide repeats in the Huntington's disease gene: quantification of the mutation frequency spectrum. *Human Molecular Genetics*, **1995**, 4, 1519-26	5.6	171
41	Neocortical dendritic pathology in human partial epilepsy: a quantitative Golgi study. *Epilepsia*, **1994**, 35, 728-36	6.4	85

40	Huntington's disease CAG trinucleotide repeats in pathologically confirmed post-mortem brains. *Neurobiology of Disease*, **1994**, 1, 159-66	7.5	70
39	A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. The Huntington's Disease Collaborative Research Group. *Cell*, **1993**, 72, 971-83	56.2	6854
38	Gametic but not somatic instability of CAG repeat length in Huntington's disease. *Journal of Medical Genetics*, **1993**, 30, 982-6	5.8	142
37	Familial aggregation of stroke. The Framingham Study. *Stroke*, **1993**, 24, 1366-71	6.7	187
36	Segregation analysis for high density lipoprotein in the Berkeley data. *Genetic Epidemiology*, **1993**, 10, 629-34	2.6	11
35	Trinucleotide repeat length instability and age of onset in Huntington's disease. *Nature Genetics*, **1993**, 4, 387-92	36.3	875
34	De novo expansion of a (CAG)n repeat in sporadic Huntington's disease. *Nature Genetics*, **1993**, 5, 168-73	36.3	226
33	Discrepancy resolved. *Nature Genetics*, **1993**, 5, 215	36.3	5
32	Evidence of presymptomatic cognitive decline in Huntington's disease. *Neuropsychology, Development and Cognition Section A: Journal of Clinical and Experimental Neuropsychology*, **1992**, 14, 961-75		52
31	Familial lipoprotein disorders in patients with premature coronary artery disease. *Circulation*, **1992**, 85, 2025-33	16.7	514
30	Family patterns of coronary heart disease mortality: the Framingham Longevity Study. *Journal of Clinical Epidemiology*, **1992**, 45, 169-74	5.7	70
29	Segregation analysis of total nevus density and estimation of lifetime risk and average onset age of melanoma. *Cytogenetic and Genome Research*, **1992**, 59, 197-9	1.9	2
28	The Huntington's disease candidate region exhibits many different haplotypes. *Nature Genetics*, **1992**, 1, 99-103	36.3	142
27	Decreased neuronal and increased oligodendroglial densities in Huntington's disease caudate nucleus. *Journal of Neuropathology and Experimental Neurology*, **1991**, 50, 729-42	3.1	172
26	Understanding the decision to take the predictive test for Huntington disease. *American Journal of Medical Genetics Part A*, **1991**, 39, 404-10		57
25	Cerebral amyloid angiopathy without and with cerebral hemorrhages: a comparative histological study. *Annals of Neurology*, **1991**, 30, 637-49	9.4	440
24	Factors associated with slow progression in Huntington's disease. *Archives of Neurology*, **1991**, 48, 800-4		174
23	Genetic linkage studies suggest that Alzheimer's disease is not a single homogeneous disorder. *Nature*, **1990**, 347, 194-7	50.4	371

22	Estimation of familial risk in Alzheimer's disease. *Annals of Neurology*, **1990**, 27, 338-40	9.4	4
21	Parental history is an independent risk factor for coronary artery disease: the Framingham Study. *American Heart Journal*, **1990**, 120, 963-9	4.9	259
20	Coronary risk associated with age and sex of parental heart disease in the Framingham Study. *American Journal of Cardiology*, **1989**, 64, 555-9	3	135
19	Using survival methods to estimate age-at-onset distributions for genetic diseases with an application to Huntington disease. *Genetic Epidemiology*, **1989**, 6, 361-71	2.6	14
18	Estimation of fertility and fitness in Huntington disease in New England. *American Journal of Medical Genetics Part A*, **1989**, 33, 248-54		14
17	Assessment of genetic risk for Alzheimer's disease among first-degree relatives. *Annals of Neurology*, **1989**, 25, 485-93	9.4	124
16	Familial Alzheimer's disease: progress and problems. *Neurobiology of Aging*, **1989**, 10, 417-25	5.6	67
15	Huntington disease: no evidence for locus heterogeneity. *Genomics*, **1989**, 5, 304-8	4.3	51
14	Predictive testing for Huntington's disease with use of a linked DNA marker. *New England Journal of Medicine*, **1988**, 318, 535-42	59.2	151
13	Considerations in using linkage analysis as a presymptomatic test for Huntington's disease. *Journal of Medical Genetics*, **1988**, 25, 577-88	5.8	22
12	Absence of duplication of chromosome 21 genes in familial and sporadic Alzheimer's disease. *Science*, **1987**, 238, 664-6	33.3	136
11	Attitudes toward presymptomatic testing in Huntington disease. *American Journal of Medical Genetics Part A*, **1987**, 26, 271-82		142
10	Huntington Disease: Neuropathological Grading. *Advances in Behavioral Biology*, **1987**, 515-531		5
9	Change in attitudes toward presymptomatic testing in Huntington disease. *American Journal of Medical Genetics Part A*, **1986**, 24, 369-71		21
8	Neuropathological classification of Huntington's disease. *Journal of Neuropathology and Experimental Neurology*, **1985**, 44, 559-77	3.1	1886
7	Attitudes toward marriage and childbearing of individuals at risk for Huntington's disease. *Social Work in Health Care*, **1984**, 9, 73-81	2	8
6	Potential impact of a predictive test on the gene frequency of Huntington disease. *American Journal of Medical Genetics Part A*, **1984**, 18, 423-9		39
5	Huntington's disease in monozygotic twins reared apart. *Journal of Medical Genetics*, **1983**, 20, 408-11	5.8	26

4	Alzheimer's disease, Down's syndrome, and aging: the genetic approach. *Annals of the New York Academy of Sciences*, **1982**, 396, 3-13	6.5	32
3	Learned aversions to intracerebral carbachol. *Physiology and Behavior*, **1977**, 19, 467-72	3.5	7
2	Comparative Huntington and Parkinson Disease mRNA Analysis Reveals Common Inflammatory Processes		1
1	Huntington disease onset is determined by length of uninterrupted CAG, not encoded polyglutamine, and is modified by DNA maintenance mechanisms		2